Compare Quest Diagnostics Inc (DGX) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Mongodb Inc — how do they compare? Quest Diagnostics Inc trades at $231.55 (market cap $25.48B), while Mongodb Inc trades at $386.94 (market cap $29.24B). The key difference: Quest Diagnostics Inc and Mongodb Inc are close in size by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Mongodb Inc for 46 Days on average.
| DGX | MDB | |
|---|---|---|
Market Cap | $25.48B | $29.24B |
Volume | 941,866 | 1,304,995 |
Sector | Health | Technology |
52-Week High | $247.45 | $472.29 |
52-Week Low | $173.49 | $225.95 |
Typical Hold Time | 56 Days | 46 Days |
Enterprise Value | $31.23B | $26.86B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
MDB trades at $383.26, up 5.57% today, with a bullish technical signal and strong analyst support. The stock is near resistance at $384 after recent volatility from a CEO transition. Fundamentally, revenue growth is robust, reaching $2.01B in 2025, but profitability remains negative with a net loss of $129M. Recent Investor Day highlighted AI product launches and raised long-term targets, fueling optimism.
Outlook is positive with 80% analyst buy ratings and a $456.76 consensus target, but risks include persistent losses, high valuation multiples, and execution challenges amid leadership changes. The stock offers growth exposure to AI-driven database demand, yet investors must weigh profitability concerns against expansion potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
